You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Oleocanthal functional food products for breast cancer recurrence control

    SBC: Oleolive, LLC            Topic: 102

    SUMMARY Triple negative breast cancer (TNBC) represents 20% of the breast cancer (BC) cases in the US. TNBC patients have a poor recurrence-free, overall survival rate, and limited treatment options. The Mediterranean olive oil-rich diet is documented to reduce BC incidence. (-)-Oleocanthal (OC) is a natural phenolic exclusively occurring in extra-virgin olive oil (EVOO). It showed selective anti- ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Antioxidant enzyme-loaded Pro-NP for treatment of TBI.

    SBC: ProTransit Nanotherapy, LLC            Topic: 106

    ABSTRACT Traumatic brain injury (TBI) is one of the leading causes of death and disability worldwide and comes with a significant economic burden associated with emergency room visits and hospitalizations. Oxidative stress- mediated secondary injury post-TBI is a considerable risk factor for mortality and long-term impairment. Immediately following TBI, a cascade of biological responses leads to i ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. An Economical Point-of-Care Software Solution Prototype for Medication Prior Authorization

    SBC: Breezmed            Topic: 104

    ABSTRACT This STTR Phase I project uses mixed-method formative evaluation strategies to develop, test, and evaluate an alpha prototype of Breezmed, a point-of-care electronic prior authorization web-based platform. Prior authorization burdens the current medical system, hampering a provider’s ability to efficiently prescribe medication and in a timely fashion. This often leads to treatment non-c ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Novel non-narcotic analgesic for acute and chronic pain

    SBC: South Rampart Pharma, LLC            Topic: 104

    Abstract Acute and chronic pain affect more than 50 million Americans and there is an enormous unmet need for safer pain relief. Although acetaminophen (ApAP) is among the medicines most commonly used for pain relief, hepatotoxicity is a risk and overdose is the most common cause of acute fulminant hepatic failure. Oxidation of ApAP to N-acetyl-p-benzoquinone imine (NAPQI) leads to hepatotoxicity. ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Noninvasive biomarkers for gastrointestinal disease in preterm infants

    SBC: Chosen Diagnostics Inc            Topic: NICHD

    The goal and significance of this project is to develop a clinically usable diagnostic test for gastrointestinal disease and to reduce healthcare costsNecrotizing enterocolitisNECis the most frequent and lethal gastrointestinal disease for preterm infantsIt affects newborns at a rate ofperUS births per year and has an average total in hospital treatment cost of $per patientAlthough first described ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Personalized Bioreactor for Cell Culturing in Alginate Tubes

    SBC: CellGro Technologies, LLC            Topic: 400

    PROJECT SUMMARY ABSTRACT SignificanceCell therapy is expected to become an important method to treat chronic diseases such as diabetesrheumatoid arthritisretinal diseases like macular degeneration and certain types of cancersThe cell therapy market in general is projected to become a $billion industry byHuman pluripotent stem cellshPSCsare of particular importance since their utility as a source f ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Nanoentrapped polyphenol coatings for sustained release from angioplasty balloons

    SBC: REQUISITE BIOMEDICAL, LLC            Topic: NHLBI

    PROJECT SUMMARYPeripheral artery diseasePADis a serious cardiovascular disease affectingmillion people worldwidePAD is defined by a blockage of arteries in the lower extremitiesand is associated with painpoor wound healingand without interventionlimb loss and deathDrug coated balloonsDCBare an emerging clinical intervention aimed at clearing blocked arteriesparticularly those that are difficult to ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Repurposing a Pinworm Drug to Treat Pulmonary Fibrosis

    SBC: SegueTX-Pancreatic Cancer, L.L.C.            Topic: NHLBI

    PROJECT SUMMARY Pulmonary fibrosis is a leading cause of death worldwide. With a median survival of only 2.5 years after diagnosis, it is responsible for millions of deaths worldwide and billions in health care costs each year. Besides mortality, pulmonary fibrosis, of which the idiopathic type is most common, brings about tragic morbidity. Without a known cause of idiopathic pulmonary fibrosis, v ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Double Chimeric Peptide Vaccine Feasible for Human Use that Protects against Disseminated Candidiasis caused by medically important Candida species

    SBC: Autoimmune Technologies, LLC            Topic: NIAID

    PROJECT ABSTRACT The goal of this Phase I STTR proposal is to develop and establish preclinical proof of concept for the first double chimeric peptide vaccine feasible for human use that protects against disseminated candidiasisDisseminated candidiasis is the third leading cause of nosocomial bloodstream infections in the USwithcases per year and associated healthcare costs of $billionanddespite t ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Peripheral Nerve-on-a-chip for Predictive Preclinical Pharmaceutical Testing

    SBC: AxoSim, Inc.            Topic: NCATS

    DESCRIPTION provided by applicant The drug development pipeline is plagued by unacceptable rates of attrition due in large part to toxicities that are not identified in pre clincal stages of development The ability to de risk lead compounds during pre clinical development with advanced andquot organoid on a chipandquot technologies show tremendous promise Chemotherapeutics in particular whi ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government